bioAffinity Technologies, Inc. (BIAF) Financial Statements
Industry: Commercial Physical & Biological Research (Services)
In fiscal 2025, bioAffinity Technologies reported revenue of $6.2M, down 34.2% from $9.4M the year before. Net income was -$14.9M (a -242.0% net margin), or -$129.90 per diluted share. Operating margin was -171.6%. Operating activities generated -$9.3M of cash, leaving -$9.4M of free cash flow. At fiscal year end, bioAffinity Technologies held $11.0M in total assets against $3.7M in total liabilities, including $6.4M of cash and equivalents.
Open the full interactive bioAffinity Technologies financials → Quarterly statements, key ratios, valuation history and price charts.
bioAffinity Technologies Key Stats
| Share Price | $3.62 |
|---|---|
| Market Cap | $1.3M |
| Revenue YoY Growth | -34.2% |
| 52-Week Range | $3.62 – $71.10 |
| Shares Outstanding | 348,450 (basic, 2026 Q2) |
bioAffinity Technologies Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $4,803 | $7.9M | $9.4M | $6.2M |
| Gross Profit | $4,336 | — | — | — |
| Operating Income | -$4.0M | -$8.0M | -$9.0M | -$10.6M |
| Pre-Tax Income | -$8.2M | -$7.9M | -$9.0M | -$14.9M |
| Income Tax | $2,459 | $20,993 | $11,650 | $44,042 |
| Net Income | -$8.2M | -$7.9M | -$9.0M | -$14.9M |
| Diluted EPS | — | -$409.50 | -$337.50 | -$129.90 |
bioAffinity Technologies Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.4M | $1.6M | $1.4M | $1.5M |
| Net Income | -$5.1M | -$3.1M | -$3.6M | -$3.4M |
| Diluted EPS | -$71.10 | -$1.82 | -$12.15 | -$9.60 |
bioAffinity Technologies Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $11.4M | $2.8M | $1.1M | $6.4M |
| Current Assets | $12.0M | $4.0M | $2.7M | $7.6M |
| Total Assets | $12.2M | $8.2M | $6.5M | $11.0M |
| Current Liabilities | $1.1M | $2.2M | $3.1M | $2.9M |
| Total Long-Term Debt | $700,000 | — | $191,849 | $146,474 |
| Total Liabilities | $1.1M | $3.4M | $3.9M | $3.7M |
| Shareholders' Equity | $11.0M | $4.9M | $2.6M | $7.3M |
bioAffinity Technologies Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$4.1M | -$6.0M | -$7.3M | -$9.3M |
| Cash From Investing | -$219,987 | -$2.2M | -$79,083 | -$60,568 |
| Cash From Financing | $14.3M | -$344,984 | $5.6M | $14.7M |
| Free Cash Flow | -$4.3M | -$6.1M | -$7.3M | -$9.4M |
Figures from bioAffinity Technologies' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full bioAffinity Technologies financials page for every line item.
bioAffinity Technologies Company Profile
| Ticker | BIAF |
|---|---|
| Exchange | Nasdaq |
| Industry | Commercial Physical & Biological Research (Services) |
| Headquarters | San Antonio, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001712762 |
Frequently Asked Questions
What was bioAffinity Technologies' revenue in fiscal 2025?
bioAffinity Technologies (BIAF) reported revenue of $6.2M for fiscal 2025.
What is bioAffinity Technologies' annual revenue history?
bioAffinity Technologies' annual revenue by fiscal year: 2022: $4,803; 2023: $7.9M; 2024: $9.4M; 2025: $6.2M.
What was bioAffinity Technologies' net income in fiscal 2025?
bioAffinity Technologies reported net income of -$14.9M for fiscal 2025.
What was bioAffinity Technologies' earnings per share (EPS) in fiscal 2025?
bioAffinity Technologies' diluted EPS was -$129.90 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did bioAffinity Technologies generate in fiscal 2025?
bioAffinity Technologies generated -$9.4M of free cash flow in fiscal 2025.
What was bioAffinity Technologies' revenue last quarter?
In its most recent reported quarter (2026 Q2), bioAffinity Technologies reported revenue of $1.5M.
How much debt does bioAffinity Technologies have?
bioAffinity Technologies reported $146,474 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of bioAffinity Technologies are outstanding?
bioAffinity Technologies reported a weighted average of 348,450 basic shares outstanding in 2026 Q2.
What is bioAffinity Technologies' market cap?
Based on its latest closing price, bioAffinity Technologies (BIAF) has a market capitalization of about $1.3M.
When does bioAffinity Technologies' fiscal year end?
bioAffinity Technologies' fiscal year end, as registered with the SEC, is December 31.
Where is bioAffinity Technologies headquartered?
bioAffinity Technologies lists its business address in San Antonio, Texas in its SEC filings.
bioAffinity Technologies Competitors & Similar Companies
See all 12 Commercial Physical & Biological Research (Services) companies →